TY - JOUR
T1 - Addition of Gallic Acid Overcomes Resistance to Cisplatin in Ovarian Cancer Cell Lines
AU - Al Balushi, Najwa
AU - Hassan, Syed Imran
AU - Abdullah, Nada
AU - Al Dhahli, Buthaina
AU - Al Bahlani, Shadia
AU - Ahmed, Ikhlas
AU - Tsang, Benjamin K.
AU - Dobretsov, Sergey
AU - Tamimi, Yahya
AU - Burney, Ikram A.
N1 - Funding Information:
This research was funded by His Majesty’s Trust Fund (HMTF) Oman, under grant number SR/MED/ MEDE/17/01. This research is part of an approved PhD student (NA) thesis.
Publisher Copyright:
© This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.
PY - 2022/8/1
Y1 - 2022/8/1
N2 - OBJECTIVE: Ovarian cancer is one of the leading causes of cancer-related mortality in women, and is often associated with drug resistance. Therefore, finding effective drugs, including naturally derived compounds, is urgently needed. Herein, we aimed to test the anti-cancer potential of gallic acid monohydrate (GA) and its congeners on cisplatin-sensitive (A2780S), and resistant (A2780CP) ovarian cancer and normal ovarian (HOSE6-3) cell lines.METHODS: Cytotoxicity was assessed by AlamarBlue and CCK08 assays by exposing cells to different concentrations of cisplatin (0-21µg/mL), GA and its congeners (0-100µg/mL), and a combination of GA and cisplatin. Apoptosis was estimated by Hoechst stain and monitoring the relative RNA expression of the apoptotic effector caspase-3 using qRT-PCR.RESULTS: GA decreased cell viability in a concentration-dependent manner in all cell lines, with an IC50 of 19.39µg/mL (A2780S), 35.59 µg/mL (A2780CP), and 49.32µg/mL (HOSE6-3). GA displayed higher cytotoxicity than its congeners. An apoptotic rate estimation of approximately 20% and 30% was obtained in A2780S and A2780CP. While the cytotoxicity observed with cisplatin and GA was comparable, combining the two enhanced the cytotoxicity significantly, especially in the A2780CP cell line (p<0.05).CONCLUSION: These data suggest that GA may help overcome the resistance. Hence, the cytotoxic effects of GA, especially on chemo-resistant ovarian cancer cells merit further investigation..
AB - OBJECTIVE: Ovarian cancer is one of the leading causes of cancer-related mortality in women, and is often associated with drug resistance. Therefore, finding effective drugs, including naturally derived compounds, is urgently needed. Herein, we aimed to test the anti-cancer potential of gallic acid monohydrate (GA) and its congeners on cisplatin-sensitive (A2780S), and resistant (A2780CP) ovarian cancer and normal ovarian (HOSE6-3) cell lines.METHODS: Cytotoxicity was assessed by AlamarBlue and CCK08 assays by exposing cells to different concentrations of cisplatin (0-21µg/mL), GA and its congeners (0-100µg/mL), and a combination of GA and cisplatin. Apoptosis was estimated by Hoechst stain and monitoring the relative RNA expression of the apoptotic effector caspase-3 using qRT-PCR.RESULTS: GA decreased cell viability in a concentration-dependent manner in all cell lines, with an IC50 of 19.39µg/mL (A2780S), 35.59 µg/mL (A2780CP), and 49.32µg/mL (HOSE6-3). GA displayed higher cytotoxicity than its congeners. An apoptotic rate estimation of approximately 20% and 30% was obtained in A2780S and A2780CP. While the cytotoxicity observed with cisplatin and GA was comparable, combining the two enhanced the cytotoxicity significantly, especially in the A2780CP cell line (p<0.05).CONCLUSION: These data suggest that GA may help overcome the resistance. Hence, the cytotoxic effects of GA, especially on chemo-resistant ovarian cancer cells merit further investigation..
KW - Antineoplastic Agents/pharmacology
KW - Apoptosis
KW - Carcinoma, Ovarian Epithelial
KW - Cell Line, Tumor
KW - Cisplatin/pharmacology
KW - Drug Resistance, Neoplasm
KW - Female
KW - Gallic Acid/pharmacology
KW - Humans
KW - Ovarian Neoplasms/metabolism
UR - http://www.scopus.com/inward/record.url?scp=85136839865&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136839865&partnerID=8YFLogxK
U2 - 10.31557/APJCP.2022.23.8.2661
DO - 10.31557/APJCP.2022.23.8.2661
M3 - Article
C2 - 36037120
AN - SCOPUS:85136839865
SN - 1513-7368
VL - 23
SP - 2661
EP - 2669
JO - Asian Pacific Journal of Cancer Prevention
JF - Asian Pacific Journal of Cancer Prevention
IS - 8
ER -
